Report of Foreign Issuer (6-k)
March 29 2017 - 7:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 or 15d-16
UNDER
THE SECURITIES EXCHANGE ACT
of 1934
For the Month of March 2017
001-37521
(Commission File Number)
INTEC PHARMA LTD.
(Translation of registrant’s name into
English)
12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel
(+972) (2) 586-4657
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________
EXPLANATORY
NOTE
On March 29, 2017, Intec
Pharma Ltd., issued a press release titled “Intec Pharma Provides Update on Phase III ACCORDANCE Study of the Accordion Pill
Carbidopa/Levodopa in Parkinson’s Disease Patients."
Copy of the press release
is attached hereto as Exhibit 99.1 and incorporated by reference into the Company’s registration statements on Form S-8 (Files
No. 333-209700 and No. 333-212801).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
INTEC PHARMA LTD.
|
|
|
|
|
By:
|
/s/ Zeev Weiss
|
|
|
Name: Zeev Weiss
|
|
|
Title: Chief Executive Officer
|
Date: March 29, 2017
|
|
|
EXHIBIT
INDEX
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Sep 2023 to Sep 2024